In this podcast episode, Sharon L. Rogers reflects on her personal experiences in Alzheimer’s disease research, from her role in bringing the drug E2020 to market as a cholinesterase inhibitor, to the current focus on beta-amyloid and tau proteins.
The speakers emphasize the complex nature of Alzheimer’s disease and the need for a holistic understanding of its causes. They discuss the challenges in Alzheimer’s research, including the history of failed drug trials, societal perceptions, and the high cost of treatments. The speakers also highlight the importance of addressing the needs of Alzheimer’s patients, including the benefits of early diagnosis and home-based treatments, and share their company’s research focusing on the T-Type calcium channel in presynaptic neurons.
